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Reactive  lysls  is  the  consequence  of  the  interaction  of  two  reagents.  One, 
previously called indicator,  is  a  normal  serum protein  and  has  been  identified 
as  C7  (1);  the  other is generated  by complement  activation from certain  sera 
(referred  to  as  "reactor"  sera)  and  has  been  called  activated  reactor.  In  this 
paper  the  nature  of  the  activated  reactor  is  explored  and  the  course  of  the 
reaction  analyzed. 
Materials  and Methods 
These are described in the preceding paper  (1).  Diisopropyl fluorophosphate  (DFP)  was 
obtained from Boots Pure Drug Co., Nottingham,  England. 
1:10  phenanthroline  hydrate  was  obtained  from  Hopkins  &  Williams,  Ltd.,  Chadwell 
Heath,  Essex, England.  A 0.5  ~  solution was made in dimethylformamide and  this  was  di- 
luted 1 : 50 in the E/EDTA/agarose mixture. 1 
Quantitation of Activated Reactor.--An estimate of activated reactor was obtained by filling 
a standard  size well in an E/EDTA/agarose plate with activated reactor and allowing diffu- 
sion to occur for 18 hr at room temperature. The plate was then immersed in 1: 50 guinea pig 
EDTA complement and  incubated  at 37°C  for 6 hr. The diameter of the zone of lysis was 
measured. 
RESULTS 
Fractionation  of  Activated  Reactor 
Absorption  with Zymosan (4 mg/ml)  and Precipitation  as Euglobulin.-- 
These were performed in the usual way. Reactor activity in the euglobulin fraction, when 
redissolved in 0.3 N NaCI, pH 7.2, was stable on storage both at 4°C and at -20°C. Addition 
of glycerol to a final concentration of 25% allows the activated reactor euglobulin to be stored, 
certainly for some months,  at  --20°C without loss  of activity. 
* The work was supported  by grants from the Nuffield Foundation and the Medical Re- 
search Council to Dr. Lachmann and from the John Squire Memorial Fund to Dr. Thompson. 
1 1% agarose plates made up in 0.01  M ethylenediaminetetraacetic  acid  (EDTA) in buf- 
fered saline and containing 1% sheep red cells (1). 
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The pseudoglobulin fraction was devoid of reactor activity, but contained an 
inhibitor  of  reactor  hemolysis.  For  this  reason,  the  euglobulin  was  a  much 
better  source  of  activated  reactor  than  whole  activated serum. 
Fractionation  on Dielhylaminoethyl  (  DEAE)-Cellulose.-- 
The activated reactor euglobulin  was  fractionated on  DEAE-cellulose  in 40%  glycerol 
containing  buffers essentially as described for the fractionation of C7 in (1). 
The starting buffer was 0.01 ~  phosphate, pH 7.9, and gradient elution  was  performed 
with 0.3 M NaCI in starting buffer. 
Activated reactor factor  (activated R)  activity was  eluted at a  conductivity of 2.8-4.0 
millimhos/cm which  in the presence  of 40%  glycerol, corresponds  approximately to 0.20 N 
NaC1. The active fractions were pooled and concentrated by positive pressure ultrafiltration 
in a Diaflo cell. 
Antigenically,  the  concentrated  material  was  markedly  heterogeneous.  It 
contained the activities of C9 and Ci  as well as of activated R. 
Fractionation  on  Sephadex  G-2OO.--The  DEAE-purified  activated  R  was 
further fractionated on Sephadex G-200. The elution diagram is shown in Fig. 1. 
Activated  R  activity was  found  in  the  fractions  immediately following  the 
exclusion peak. 
The  activated R  from the Sephadex column had a  protein concentration of 
220  /~g/ml.  and  was  purified  about  300-fold,  compared  to  the  activated  R 
euglobulin. Because of the limited amount of material available, further purifi- 
cation was not attempted. 
The preparation was still contaminated with Ci as shown by its inactivation 
of  C4.  This  activity was  removed by treatment  with 10  -3 ~  DFP  which had 
no  effect  on  activated R  activity. The  DFP-treated preparation was  used  as 
"functionally-purified" activated R. 
On  examination  in  Ouchterlony  plates,  the  functionally pure  activated  R 
gave  several lines with  a  highly polyvalent anti-human  globulin serum.  One 
of these  gave a  line of identity with  anti-C3  (Fig.  2)  and  another  was shown 
separately to  give a  line of  identity with  anti-IgG. Precipitin lines with  anti 
C5  and with  anti-C6  were faint.  However, it may be  seen  in  Fig.  2  that  the 
lines given by anti-C5  and anti-C6 fuse, indicating that these two components 
were  complexed in  activated R. 
Molecular  Weight  of  Activated  Reactor.--The  sedimentation  coefficient  of 
activated R  was measured by sucrose gradient ultracentrifugation (Fig. 3)  and 
was  found  to  be  11.7  S  (mean  of  three  values). 
The  duffusion  coefficient was measured  by two  techniques: 
Firstly, the L-plate method  of Allison and  Humphrey  (2)  was  used.  Activated R  was 
diffused against C7 in E/EDTA/agarose plates. After 48 hr, the plate was immersed in guinea 
pig EDTA-C  to develop  the hemolytic line.  This llne formed  at an angle of 39  ° with the 
trough containing  activated R. Since the diffusion coefficient of C7 is known to be 4.0 (1) the 
diffusion coefficient of activated R could be calculated to be 2.6 X  10-Tcme/sec. P. j. LACHMANN  AND  R. A. THOMPSON  645 
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Secondly,  a  value for the diffusion coefficient was  calculated from  the Sephadex  G-200 
fractionation by ptotting the elution volume against 1/D  (3). Taking a value of 6.8 for the 
diffusion coefficient of hemoglobin  (peak at tube 204) and of 3.8 for IgG (peak at tube 130) 
the diffusion coefficient of the exclusion peak (peak at tube 80)  is equal to or less than 2.9 
and the diffusion peak of activated R  (peak at tube 100) is 3.2. 
Taking the measured values of  11.7  for s~o.~ and  the  mean value of 2.9 for 
&o,~o,  and  assuming  a  value  of  0.73  for  the  partial specific volume  (7),  the 
molecular weight was calculated by the Svedberg equation to be  in the region 
of 360,000  and the frictional ratio was calculated by Oncley's  equations  to  be 
in the region of 1.6. 
FIG. 2. The antigenic analysis of functionally purified activated R. The center well contains 
functionally purified Activated R. The numbered wells contain: 1. Anti-C3 [F(abr)2 fraction]; 
2.  Polyvalent anti-human globulin  serum  1; 3. Anti C5  (IgG fraction).  (This fraction con- 
tains some human serum protein); 4. Anti C6 IgG; 5. Anti C3 [F(ab')2 fraction]; 6. Polyvalent 
anti-human globulin serum 2. 
Antigenic  Identification  of Activated  Reactor  by Inhibition of Reactive Hemol- 
ysis.--Specific antisera were tested for their capacity to inhibit reactive hemol- 
ysis. IgG fractions of antiserum or F(ab')2 fractions  of purified antibody  ~ were 
used  to  avoid nonspecific inhibition. 
The following patterns of reactivity were observed: 
No  inhibition  (Fig. 4a)  where  the  hemolytic lines showed  no  interruption. 
This was found with antibody to immunoglobulins G, A, M, and D; to C4 and 
to C3;  and to properdin. 
Inhibition  of  indicator  (Fig.  4b)  where  the  hemolytic lines  were  deviated 
2 Lachmann,  P. J. The purification of specific antibody F(ab')2 by the pepsin digestion of 
antigen-antibody precipitates.  Manuscript  submitted  for  publication. P. ].  LACHMANN  AND  i~. A. THOMPSON  647 
and inhibited by a reaction between antibody and indicator. This pattern was 
shown only by antibody to indicator (C7)  (1). 
Inhibition  of  activated  reactor  (Fig.  4c)  where  the  hemolytic lines  were 
deviated and inhibited by a reaction of antibody with reactor. 
This pattern was  always given by anti-C5  and anti-C6.  Anti-C8 also gave 
this  pattern  when  an  activated  R  euglobulin was  used  with  purified  C7  as 
source of indicator.  However, when purified activated R  was  used  and  the 
hemolytic lines  developed  with  guinea  pig  EDTA-complement  (see  below) 
anti-C8 was not inhibitory. 
This analysis indicates that activated R  contains C5 and C6. The molecular 
125  zThyroglobulin 
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FIo. 3. The ultracentrifugal analysis of activated R. A 4.8 ml linear sucrose gradient from 
8-36% sucrose was used. 0.2 ml activated R  containing the markers was applied. Centrifuga- 
fion was performed in a  Spinco SW39 rotor for 20 hr at 35,000 rpm.  10-drop fractions were 
collected from the bottom of the tube and tested as shown. 
weight of C6 is around 150,000 (4) ; that of C5, with a sedimentation coefficient 
of 8.7  S is likely to be above 200,000.  Activated R  with a molecular weight in 
the  region of 360,000  can therefore contain only one molecule of each.  The 
data is insufficiently accurate to exclude the presence of another much smaller 
molecule in the complex. 
The Role of C8 and C9 in Reactive Lysis.--When functionally purified prep- 
arations of activated R  and C7 were tested in red cell containing plates, lines 
of lysis were not seen after interaction but could be developed by immersing 
the  plates  briefly  in  dilute  guinea  pig  EDTA-C.  Prolonged  incubation  in 
EDTA-C  gave zones of lysis wherever activated R  was present in the  plate 
and may be used as a method for quantitating activated R. 
Table  I  shows  the  hemolytic lines  obtained  using  various  indicator  and 
activated reactor reagents. 648  REACTIVE  LYSIS.  II 
FIG. 4. The antigenic analysis of reactive lysis by inhibition of hemolysis by antisera.  (a) 
shows no inhibition. The inhibiting antibody is anti-C3 which gives a line of precipitation with 
activated R.  (b)  shows  inhibition of indicator. The inhibiting antibody is anti-CT.  (c)  shows 
inhibition of activated R. The inhibiting antibody is anti-C6. R, activated R, 7, C7. Ab, IgG 
fraction of antiserum.  The unlabeled wells contained saline. P.  j.  LACI:I-MANN  AND  R.  A.  THOMPSON  649 
It can be seen that both C8  and  C9  are needed for hemolysis to occur and 
that  it is  immaterial in  which  reagent  they  are present.  The  need  for  C9  is 
abolished if 0.01 M phenanthroline is incorporated in the plate (5). 
It is concluded that the primary product of the interaction of activated R 
and C7 in the presence of red cells (E) is EC567. 
Reactive Hemolysis in the Test Tube.--Although it is convenient to carry out 
reactive hemolysis in immunodiffusion plates, the reaction works  equally well 
in the test tube. 
TABLE I 
Hemolytic Lines Obtained Using Various Indicator and Activated Reactor Agents 
Source of activated R 
Activated R euglobulin (C5-6, C8, 
C9) 
DEAE fraction (C56, C9) 
DEAE fraction (C5-6), C9) 
Functionally pure (C5"6) 
Functionally pure (C~.6) 
Functionally pure (C56) 
Functionally pure (C56) 
Source of C7 
Functionally pure (C7) 
Functionally pure (C7) 
DEAE fraction (C7, C8) 
Normal euglobulin  (C7, C8, C9) 
DEAE fraction (C7, C8) 
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* Produces circular zones of hemolysis after incubation for several hours. 
Late acting complement components  present in the various reagents are shown in paren- 
thesis.  Diffusion between  activated R  and C7 takes place overnight at room  temperature. 
Phenanthroline plates contain a  final concentration of 0.01 M phenanthroline.  Plates are 
immersed in 1:50 guinea pig serum in 0.01 M EDTA for 15 min at 37°C to develop hemolytic 
ines.  +, hemolytic line present; 0, no hemolytic line; --, not done. 
When E  was mixed with functionally purified activated R  and an equivalent 
amount of C7 then added, no lysis occurred but the cells acquired the capacity 
to be lysed by guinea pig EDTA-C.  This  activity is  "heat  stable"  as shown 
in Fig. 5b and corresponds to the hemolytic activity of EC567. 
Although the EC567  cells are so stable once they are formed,  the  capacity 
of  the product  of  activated reactor  and  C7  interaction to form  these  cells is 
very short lived having a half life of 1 min or less (Fig. 5a). 
Titrations  of the  functionally purified C7  and  activated reactor  were  per- 
formed in  the presence  of excess of the  other reagent  to  determine  the least 
amounts necessary to produce EC567.  The C7 preparation with a protein con- 
centration of 280 ~g/ml had a  titer of 600,  i.e., about 45 m~g were needed to 650  I~ACTIVE LYSIS. II 
give 50 %  hemolysis of about  107E.  The activated reactor with a  protein con- 
centration of 220/zg/ml had a  titer of 170,  i.e.,  130/m/zg were needed to give 
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FIG. 5. The heat stability of C567 for making EC567 and of EC567 for lysis by EDTA-C 
(a) Activated R and C7 were mixed at 37°C. After the incubation period E was added and 
incubation continued for 15 min at 37°C, when guinea pig EDTA-C was added. Lysis was 
measured  after a further 30 rain at 37°C. (b) EC567 were incubated at 37°C. After the in- 
cubation period, the cells were suspended in guinea pig EDTA-C, 0.01 ~  phenanthroline, or 
in diluent alone and incubated for 30 rain more at 37°C before measuring  lysis. 
of 2 X  1@ molecules/red cell, assuming the preparation to be pure. Since, how- 
ever, Oil a protein basis, some of the indicator preparation is IgG and much of 
the activated reactor is/~-globulin, this figure is a considerable overestimate. 
There was no inhibition of lysis by excess of either reagent. 
Antigenic  Analysis of EC567 made with Activated R  and C7.--EC567  made 
with 10 times the 50 %  hemolytic endpoint were analyzed antigenically by the P. J. LACIIMANN  AND  R. A.  THOMPSON  651 
use  of specific antibodies to  complement  components.  The  results  are shown 
in  Table  II.  It  is  seen  that  C5  is  the  main  agglutinogen  on  these  cells and 
anti-C5 was the only antiserum to give agglutination strong enough to be read 
by the resuspension technique. Anti-C6 and anti-C7 also agglutinated the cells, 
whereas anti-C4 and anti-C3  quite failed to do so.  The absence of C3  on the 
cells was confirmed by their failure to react in immune adherence or with con- 
glutinin in the presence of conglutinogen-activating factor (KAF). Two serum 
TABLE II 
Characterization of Reactive Hemolysis Cells as EC567 by the Antiglobulin Reaction 
Agglutinating  serum  Indicator ...... 
Titer of agglu- 
tinating serum 
Control~ 
Reactive hemolysis cells*  E  cells 
25  125  625  3125  15,6255  5 
Anti-C4 IgG  0  0  0  0  0  0  0 
Anti-C3 IgG  0  0  0  0  0  0  0 
Anti-C5 IgG  ++  ++  ++  ++  +  0  0 
Anti-C6 IgG  ++  ++  0  0  0  0  0 
Anti-C7 IgG  -k-+  ++  -}-  0  0  0  0 
Anti-C8 IgG  0  0  0  0  0  0  0 
Anti-properdin IgG  0  0  0  0  0  0  0 
Titer  on EAC  rabbit: 
Human salivary IK  >2000  +  +  0  0  0  0  0 
Rabbit serum IK [R150]  >2000  0  0  0  0  0  0  0 
Rabbit serum IK 1197/  >2000  0  0  0  0  0  0  0 
6/6 




10 doses conglutinin  0  0  0 
10 doses conglufinin  +  KAF  0  0  0 
Immune adherence  0  0  0 
* 1 ml purified  DFP-treated activated R, +  1 ml 10% E +  0.2 ml. C7/5  rain, 37°C, 
washed well. 
:~ 1 ml purified DFP-treated activated R, +0.2 ml C7/5 rain 37°C/1  ml. 10% E/5 rains. 
37°C, washed well. 
immunoconglutinins  also  failed  to  agglutinate  the  cells  but  immunocon- 
glutinins (IK) from human saliva (6) did agglutinate them to a low titer, indi- 
cating that autoantibodies to the 567  determinants can be formed. 
The Interaction  between Activated  Reactor  and C7 in  the Absence of Cells.- 
When activated R  and C7 interact in solution, the hemolytic activity of their 
product was rapidly lost (Fig. 5a). However, this hemolytically inactive C567 
still inactivated C8 and the capacity to do so was quite stable (Table III). 
If  C8  was  present,  the  resulting  C5678  inactivated  C9.  Thus  the  DEAE 
fraction of activated R  may be freed of C9 by the addition of one-fifth of its 
equivalent amount  of the DEAE  fraction of C7,  which  also contains C8,  but 652  REACTIVE  LYSIS.  II 
not  by  the  same  amount  of  C7  alone.  Similarly,  if just  sufficient activated  R 
was  added  to  normal  human  serum  to  destroy  its hemolytic  activity on  EA, 
the  resulting  reagent  was  depleted  of  C9  and  with  EA  gave EAC  1  ~-~  8.  If 
enough activated  R  to deplete  all the  C7 was used,  the resulting reagent gave 
rise to EAC 1 ~  3. 
TABLE III 
The  Consumption of C8 by Activated R-C7 Complex 
Added to titration of C8 
Dilution of C8 Preparation 
33  100  300  900  2700  Diluent 
C7  ++  ++  ++  +  (+)  0 
Activated R; mix; then C7  ++  0  0  0  0  0 
Activated R  -- C7 preincubated 5 min at  ++  (+)  0  0  0  0 
37°C * 
* Incubation of the activated R-C7 (C567) complex for 1 hr at 37°C or overnight at 4°C 
have been found not to affect its capacity to inactivate C8. 
C7:  approximately  2 #g  of  the most  highly purified  material  was  used.  Activated R: 
DEAE-fractionated activated R was used.  The amount was one-fifth of the amount  equiva- 
lent to 2 gg C7. All mixtures therefore contained ample free C7. The final mixtures were al- 
lowed to diffuse  in E/EDTA/agarose plate,  incorporating 0.01  •  phenanthroline  against a 
functionally purified activated R preparation. 
The scoring describes lines of reactive hemolysis.  ++,  line of complete hemolysis.  +, 
obvious line of partial hemolysis. (+), weak line of partial hemolysis. 
TABLE IV 
Lines of reactive lysis given by  sera treated  with 
Source of serum  Anti-a~  Anti C7 IgG 
Saline  macroglobulin  IgG 
Normal (nonreaetor)  0  0  + 
Acute phase (reactor)  +  +  + + 
0.5  ml of serum was treated with 0.1 ml IgG preparation for 30 min at 37°C and centri- 
fuged. The supernatants  with Ca and Mg restored were tested for reactor activity in plates 
by diffusion  against a C7 preparation. 
The  Properties  Conferring  Reactor  Activity  on  a  Serum.--The  capacity  to 
generate  activated  R  has  been found  in  a  minority of human  sera--generally 
those  in  the  "acute  phase"  of  inflammation  (9)  and  the  factors  that  confer 
reactor  activity on  these  sera  are  not  known. 
It seems  quite likely that  the balance  between the amount  of  C~  that  can 
be generated and the amount of C7 that is available to react with it determines 
whether  a  serum  (after  zymosan  absorption)  contains  activated  R  or  C7  or 
neither. 
Evidence  in  support  of  this  view has  been  obtained  by  showing  that  non- P.  J.  LACHMANN  AND  R.  A.  THOMPSON  653 
reactor serum treated with anti-C7 IgG acquired reactor activity (Table IV). 
Further evidence for this view has been obtained by studying C7 levels in a 
hospital  population  and  comparing these  with  the  incidence  of reactor sera. 
The results shown in Fig.  6 demonstrate that the incidence of reactor sera is 
highest at the lowest C7 levels and falls steadily with increasing amounts of C7. 
Finally preliminary studies carried out using reagents kindly made available 
by Dr.  S.  Ruddy,  have shown  that  activated R  could  be generated  by the 
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FIG. 6. (a) The serum concentration of indicator (C7) in 250 medical and surgical hospital 
patients. (b) Incidence of reactor activity in different indicator ranges. C7 levels were meas- 
ured as described in (1). 
interaction of partially purified preparations of C5  and C6, with EAC14°xY23, 
but not with EAC14°xy2. 
The  possibility  that  properdin  which  occurs  in  greater  quantity  in  acute 
phase sera might be involved in the generation of reactor was also considered. 
However antiserum to properdin, kindly supplied by Dr. G. Naff, was without 
inhibitory effect on reactive hemolysis and  did not  agglutinate EC567  made 
with  activated  R  and  C7.  If  therefore properdin  plays  any part  in  reactor 
activity it does so without being incorporated into activated R. 654  REACTIVE LYSIS. II 
DISCUSSION 
Fig.  7  shows  schematically the process of reactive hemolysis as it emerges 
from  the experiments that have been described. 
Complement activation in certain sera leads to the generation of activated R 
(C5-6), a stable complex involving the fifth and sixth components of complement 
in 1:1  combination. This is always associated with loss of C7  and is believed 
to reflect a relative excess in these sera of C56 over C7. In support of this view 
Acute  phase  serum  or  Normal  seruln 
treated  with  anti-C7 
I 
I  Normal  serum 
Zymosan 
37°C 
Activated  P,  ed ctor  Indicator 
Cs~  C7 
l  I 
L 
Cg'E?  [Half  Life ~30 seconds  at 37°C] 
ECs67  In Agarose  C~-~  No longer binds to cells, 
still inactivates Ca and C9 in solution. 
Binds  to Gel. 
Hemolysis  gives 
"stainable  line" 
FIG. 7. Schematic representation of reactive lysis. The bar on C56 and C567 refers to activa- 
tion of the site that allows them to react with subsequent  component.  The asterisk C567" 
refers to activation of the binding site. 
are the observations: (a) that depleting C7 in normal sera with anti-C7 causes 
them to behave as reactor sera; (b) that reactor sera usually have low levels of 
C7; and (c)  that treating C5  and C6 with EAC1423  gives rise to activated R. 
It remains unclear why some complement activating systems, e.g., zymosan 
and its natural antibody, or lightly sensitized Proteus should be so much better 
at generating activated R  than,  for example, aggregated gamma globulin (9), 
but the factors involved are presumably the same that cause these polysaccha- 
ride systems to be so good at making reagents mainly depleted in late comple- 
ment components. 
The interaction of C56 with C7 gives rise to a  complex which has for a  brief P.  J.  LACHMANN  AND  R.  A.  THOMPSON  655 
period the capacity to attach to erythrocyte and, according to preliminary evi- 
dence, to nucleated cell membranes; to bacteria; to other hydrophobic surfaces 
including lipid emulsions; and to agarose gel where the binding can be seen as 
a  "stainable line". The fixed complex confers on cells  the hemolytic activity 
associated with the "heat stable" complement intermediate EAC 1 ~  7. The 
lysis produced by reactive hemolysis has been shown in association with Dr. 
R. R. Dourmashkin to show the same electron microscopic lesions as are found 
in normal immune hemolysis. The heat stable cells made by reactive hemolysis, 
however, have neither antibody nor the earlier complement components bound 
on them. They are thus negative in immune adherence. This emphasises that 
the  hemolytic process  requires  the  complement  activation as  far  as  the  C3 
stage, only to generate C56 which can then provoke lysis in conjunction with 
the later components. 
Immune hemolysis of cells bearing only complement components after the 
C5  stage has also been produced by a  somewhat different method  by G6tze 
and Mtiller-Eberhard (10). 
If the activated C567 complex fails to bind to membrane, it rapidly loses the 
capacity to do so and appears in solution as a stable complex that remains able 
to inactivate C8  and  C9 in solution.  Experiments to be published elsewhere 
have shown that  this binding site inactivated C567  complex has  chemotactic 
activity for neutrophils and thus corresponds to the C567 chemotactic factor 
generated in the normal complement fixation reaction (11).  3 
The evanescent activation of the binding site of C5-6-7 and the simultaneous 
long-lasting  activation  of  its  hemolytic site  is  very similar  to  the  situation 
described for C4 by Mtiller-Eberhard and his colleagues (12). 
It would seem highly probable that the reaction of C5,  C6,  and C7  in the 
normal complement sequence follows basically the same pattern as in reactive 
hemolysis; the generation of C5--6 (in this case, presumably held loosely at the 
complement fixation site), the interaction with C7 and subsequent firm binding 
to the cell membrane and the acquisition of the heat stable hemolytic property. 
This mechanism would be intermediate between the "sequential action" and 
"functional unit" mechanisms of C5,  C6,  and C7  action discussed by Nilsson 
and Mtiller-Eberhard (13)  and would explain why the intermediates between 
EAC  1 ~  3  and EAC  1 ~  7 are unstable. 
One  difference between the  two  situations  however lies  in  the  amount  of 
C567  bound  to  cells.  In  the  normal  complement sequence,  the  majority of 
C567  escapes into solution,  and the amount of C5  bound  (0.5 %  of input)  is 
too small to be detected antigenically with an anti-C5 serum (13,  14).  EC567 
made with activated R and C7 are on the other hand very strongly agglutinated 
by anti-C5.  The difference may reflect the much greater  area of membrane 
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available if C56  is generated in solution  and  not  at  the  complement fixation 
site, or it may be that the coating of the cell with C3 limits the uptake of C567. 
The significance of reactive hemolysis in vivo is not known.  It provides a 
mechanism by which  complement activation at one site can lyse normal cells 
at  a  distance,  but  the  extent  to  which  reactive  hemolysis  as  a  mediator  of 
"immune complex" damage has still to be evaluated. It would however seem 
quite likely that the lysis of paroxysmal nocturnal hemoglobinuria (PNH) cells 
is due  to reactive hemolysis.  PNH cells have been found in our hands  to be 
extremely sensitive  to  reactive hemolysis and  there  is  already  evidence  (15) 
that fluid phase complement activation is associated with PNH cell lysis. 
Whatever its role in vivo, in vitro the phenomenon provides a useful tool for 
the study of the late stages of complement action. It provides the basis for re- 
producible  test systems for the  late-acting  complement components,  and  in- 
hibitors and antibodies to them, without the need for extensively purified prep- 
arations of all nine components. For example it has already been shown using 
these cells that there is an agglutinogen in EC567 recognized by human salivary 
I-K's so that this is a further complement intermediate that is autoantigenic. 
SUMMARY 
It has been shown that the "activated reactor" that is produced in certain 
human sera by complement activation is a stable complex of the fifth and sixth 
component of complement (C5-6). On interaction with C7, the indicator factor, 
a complex C567 is formed which for a short time (half-life less than 1 min) has 
an activated binding site and can attach itself to normal red cell membranes, 
conferring on them the hemolytic properties of the "heat stable" complement 
intermediate EC  1 ~  7,  the  capacity to be lysed by C8  and  C9.  These cells 
have  neither  antibody nor  the  complement components up  to  C3  bound  on 
them. 
The binding site~activated C567c--can similarly bind to other hydrophobic 
surfaces, including agarose gel where it forms a  "stainable line". 
If the  complex is not bound  to  a  surface,  the binding  site decays and  the 
resulting complex will no longer give rise to lysis. However it will still inactivate 
C8 and C9 in solution. The sera that can generate activated reactor apparently 
do so because they have an excess of C5  and  C6,  compared to their  content 
of C7. 
The  phenomenon  of  reactive  lysis  thus  represents  complement-mediated 
lysis of unsensitized  cells initiated at the C5  stage by a  stable complex (C5-6) 
which was generated by complement activation at a distance. 
The immunochemistry of the phenomenon is described and some of its impli- 
cations discussed. 
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